Joseph L Izzo Selected Research

Olmesartan Medoxomil (Votum)

1/2014	Triple-combination treatment with olmesartan medoxomil/amlodipine/ hydrochlorothiazide in Hispanic/Latino patients with hypertension: the TRINITY study.
7/2013	Combined olmesartan, amlodipine, and hydrochlorothiazide therapy in randomized patients with hypertension: a subgroup analysis of the TRINITY study by age.
3/2012	Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide for hypertension.
3/2012	Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study.
12/2011	24-hour efficacy and safety of Triple-Combination Therapy With Olmesartan, Amlodipine, and Hydrochlorothiazide: the TRINITY ambulatory blood pressure substudy.
1/2007	Titration of HCTZ to 50 mg daily in individuals with stage 2 systolic hypertension pretreated with an angiotensin receptor blocker.
1/2007	Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study.
2/2006	Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.
9/2002	Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Joseph L Izzo Research Topics

Disease

38	Hypertension (High Blood Pressure) 01/2019 - 06/2002
9	Isolated Systolic Hypertension 06/2017 - 06/2002
7	Chronic Renal Insufficiency 04/2016 - 05/2003
5	Cardiovascular Diseases (Cardiovascular Disease) 01/2019 - 05/2003
5	Heart Failure 07/2013 - 03/2010
4	Type 2 Diabetes Mellitus (MODY) 01/2019 - 02/2006
3	Obesity 11/2011 - 11/2003
3	Stroke (Strokes) 09/2011 - 03/2010
2	Hyperaldosteronism (Conn Syndrome) 01/2019 - 01/2019
2	Glucocorticoid-Remediable Aldosteronism 01/2019 - 01/2019
2	Coronary Artery Disease (Coronary Atherosclerosis) 07/2013 - 09/2011
2	Renal Insufficiency (Renal Failure) 07/2013 - 09/2011
2	Heart Diseases (Heart Disease) 11/2012 - 09/2004
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 11/2011 - 04/2011
2	Myocardial Infarction 09/2011 - 03/2010
1	Vascular Diseases (Vascular Disease) 01/2019
1	Body Weight (Weight, Body) 01/2019
1	Aortic Coarctation 01/2016
1	Aortic Diseases 12/2014
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 07/2013
1	Diabetes Mellitus 08/2012
1	Angioedema 09/2011
1	Cough 09/2011
1	Hyperkalemia 09/2011
1	Hypotension (Low Blood Pressure) 09/2011
1	Diabetic Nephropathies (Diabetic Nephropathy) 04/2011
1	Myocardial Ischemia (Ischemic Heart Diseases) 04/2011
1	Coronary Disease (Coronary Heart Disease) 03/2011
1	Masked Hypertension 03/2010
1	Prehypertension 08/2007
1	Hypercholesterolemia 08/2007
1	Prediabetic State (Prediabetes) 08/2007
1	Gout 01/2007
1	Proteinuria 02/2006
1	Albuminuria 02/2006
1	Edema (Dropsy) 08/2005
1	Essential Hypertension 09/2002

Drug/Important Bio-Agent (IBA)

15	Antihypertensive Agents (Antihypertensives)IBA 01/2019 - 05/2003
13	Hydrochlorothiazide (Esidrix)FDA LinkGeneric 02/2017 - 01/2007
11	Amlodipine (Norvasc)FDA LinkGeneric 01/2014 - 03/2008
9	Olmesartan Medoxomil (Votum)FDA Link 01/2014 - 09/2002
8	Angiotensin Receptor AntagonistsIBA 02/2017 - 05/2003
7	olmesartanIBA 07/2013 - 01/2007
6	Valsartan (Vals)FDA Link 06/2017 - 03/2008
6	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 11/2012 - 06/2002
6	Pharmaceutical PreparationsIBA 03/2010 - 05/2003
4	ReninIBA 05/2012 - 11/2003
3	ThiazidesIBA 02/2017 - 05/2003
3	AngiotensinsIBA 05/2012 - 08/2007
3	aliskiren FDA Link 11/2011 - 04/2011
3	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 08/2005 - 05/2003
2	Amiloride (Midamor)FDA LinkGeneric 01/2019 - 01/2019
2	Epithelial Sodium ChannelsIBA 01/2019 - 01/2019
2	AldosteroneIBA 01/2019 - 05/2012
2	Sodium Chloride Symporter Inhibitors (Diuretics, Thiazide)IBA 02/2017 - 12/2003
2	DiureticsIBA 04/2016 - 05/2003
2	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 11/2012 - 04/2011
2	Renin InhibitorsIBA 11/2011 - 09/2007
2	Enalapril FDA LinkGeneric 11/2005 - 06/2002
2	omapatrilatIBA 11/2005 - 06/2002
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2019
1	Sodium-Glucose Transport ProteinsIBA 01/2019
1	Hypoglycemic Agents (Hypoglycemics)IBA 01/2019
1	empagliflozinIBA 01/2019
1	sacubitril and valsartan sodium hydrate drug combinationIBA 06/2017
1	sacubitrilIBA 06/2017
1	SteroidsIBA 01/2016
1	Cardiovascular AgentsIBA 12/2014
1	Sodium Potassium Chloride Symporter Inhibitors (Loop Diuretics)IBA 05/2012
1	EnzymesIBA 09/2011
1	Valsartan Drug Combination Amlodipine FDA Link 03/2008
1	Angiotensin Receptors (Angiotensin II Receptor)IBA 08/2007
1	Uric Acid (Urate)IBA 01/2007
1	Vasopeptidase InhibitorsIBA 11/2005
1	Biomarkers (Surrogate Marker)IBA 11/2005
1	Enzyme Inhibitors (Inhibitors, Enzyme)IBA 11/2005
1	Glucose (Dextrose)FDA LinkGeneric 11/2003
1	Neprilysin (Neutral Endopeptidase)IBA 06/2002
1	Indicators and Reagents (Reagents)IBA 06/2002
1	Natriuretic PeptidesIBA 06/2002

Therapy/Procedure

18	Therapeutics 01/2019 - 05/2003
3	Drug Therapy (Chemotherapy) 03/2010 - 07/2009
1	Denervation 01/2016
1	Catheter Ablation 01/2016
1	Ambulatory Care (Outpatient Care) 07/2013